|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase. (11)Lyon, France: http://globocan.iarc.frOctober 5–2014
|
|
2
|
Ooi SL, Martinez ME and Li CI: Disparities
in breast cancer characteristics and outcomes by race/ethnicity.
Breast Cancer Res Treat. 127:729–738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Justo N, Wilking N, Jönsson B, Luciani S
and Cazap E: A review of breast cancer care and outcomes in Latin
America. Oncologist. 18:248–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Villarreal-Garza C, Aguila C,
Magallanes-Hoyos MC, Mohar A, Bargalló E, Meneses A, Cazap E, Gomez
H, López-Carrillo L, Chávarri-Guerra Y, et al: Breast cancer in
young women in Latin America: An unmet, growing burden. Oncologist.
18:1298–1306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feeley LP, Mulligan AM, Pinnaduwage D,
Bull SB and Andrulis IL: Distinguishing luminal breast cancer
subtypes by Ki67, progesterone receptor or TP53 status provides
prognostic information. Mod Pathol. 27:554–561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang XR, Sherman ME, Rimm DL, Lissowska J,
Brinton LA, Peplonska B, Hewitt SM, Anderson WF,
Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in
risk factors for breast cancer molecular subtypes in a
population-based study. Cancer Epidemiol Biomarkers Prev.
16:439–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spitale A, Mazzola P, Soldini D,
Mazzucchelli L and Bordoni A: Breast cancer classification
according to immunohistochemical markers: Clinicopathologic
features and short-term survival analysis in a population-based
study from the South of Switzerland. Ann Oncol. 20:628–635. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vallejos CS, Gómez HL, Cruz WR, Pinto JA,
Dyer RR, Velarde R, Suazo JF, Neciosup SP, León M, de la Cruz MA,
et al: Breast cancer classification according to
immunohistochemistry markers: Subtypes and association with
clinicopathologic variables in a peruvian hospital database. Clin
Breast Cancer. 10:294–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American Society of Clinical Oncology/College of American
Pathologists: American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. Arch Pathol Lab
Med. 131:18–43. 2007.PubMed/NCBI
|
|
16
|
Bastien RR, Rodríguez-Lescure Á, Ebbert
MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson
D, Lyons B, et al: PAM50 breast cancer subtyping by RT-qPCR and
concordance with standard clinical molecular markers. BMC Med
Genomics. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu KC and Anderson WF: Rates for breast
cancer characteristics by estrogen and progesterone receptor status
in the major racial/ethnic groups. Breast Cancer Res Treat.
74:199–211. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carvalho FM, Bacchi LM, Pincerato KM, Van
de Rijn M and Bacchi CE: Geographic differences in the distribution
of molecular subtypes of breast cancer in Brazil. BMC Womens
Health. 14:1022014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meijer SL, Wesseling J, Smit VT, Nederlof
PM, Hooijer GK, Ruijter H, Arends JW, Kliffen M, van Gorp JM, Sterk
L, et al: HER2 gene amplification in patients with breast cancer
with equivocal IHC results. J Clin Pathol. 64:1069–1072. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alarcon-Rozas AE, Cueva MR, Galarreta J,
Torres J, Gonzales E and Ramirez J: Features of recurrence of
triple-negative (TN), non-metastatic breast cancer (NMBC) patients:
A single institution study. J Clin Oncol. 29:abstr 1802011.
View Article : Google Scholar
|
|
21
|
Camejo N, Gonzalez V, Castillo C, Delgado
L, Ferrero L, Fresco R, Santander GK, Aguiar S, Heinzen S, Martinez
A, Meyer C, Sena G, Spera G, Ubillos L, Xavier F, Rodriguez R and
Sabini G: Survival analysis of breast cancer subtypes assessed by
hormone receptors and HER2 tumor expression in Uruguayan women with
operable breast cancer. J Clin Oncol. 29:e210642011. View Article : Google Scholar
|
|
22
|
Abuchacra LD, Alvarado GJ, Ferretti CN,
Gómez AL, Hernández PA, Sánchez N and Sidan MJ: Relación entre la
clasificación según tipos histológicos y subtipos moleculares más
frecuentes de carcinoma mamario entre los años 2007 y 2012 en San
Miguel de Tucumán, Argentina. CIMEL. 17:76–91. 2012.
|
|
23
|
de Macêdo Andrade AC, Ferreira J, únior
CA, Dantas G, uimarães B, Barros AW Pessoa, de Almeida G Sarmento
and Weller M: Molecular breast cancer subtypes and therapies in a
public hospital of northeastern Brazil. BMC Womens Health.
14:1102014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martinez ME, Wertheim BC, Natarajan L,
Schwab R, Bondy M, Daneri-Navarro A, Meza-Montenegro MM,
Gutierrez-Millan LE, Brewster A, Komenaka IK, et al: Reproductive
factors, heterogeneity, and breast tumor subtypes in women of
mexican descent. Cancer Epidemiol Biomarkers Prev. 22:1853–1861.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sánchez V Perez, Maldonado-Mtz HA, De
León, Trenado D, Bargalló Rocha E, Dragan A Stankov, Miranda A
Alvarado, Gaona A Ojeda and Medina F Lara: Breast Carcinoma in
Mexican Women, Molecular Subtypes Using Immunohistochemical
Surrogate Markers E. J Cancer. 14(S1)2012.Abstract 181.
|
|
26
|
Smith RA, Andrews K, Brooks D, DeSantis
CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW
and Wender RC: Cancer screening in the United States, 2016 A review
of current American Cancer Society guidelines and current issues in
cancer screening. CA Cancer J Clin. 66:96–114. 2016. View Article : Google Scholar : PubMed/NCBI
|
